Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma

June 15, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search